Bolt Biotherapeutics (BOLT) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Bolt Biotherapeutics (BOLT) and Amarin (AMRN)
TipRanksNov 19 02:00 ET · Ratings
Bolt Biotherapeutics' Restructuring Faces Potential Setbacks: A Closer Look
TipRanksNov 14 01:00 ET
Stifel Maintains Bolt Biotherapeutics(BOLT.US) With Hold Rating, Maintains Target Price $1.5
Moomoo NewsNov 13 08:31 ET · Ratings
Bolt Biotherapeutics Analyst Ratings
BenzingaNov 13 08:25 ET · Ratings
H.C. Wainwright Maintains Bolt Biotherapeutics(BOLT.US) With Hold Rating
Moomoo NewsNov 13 06:31 ET · Ratings
H.C. Wainwright Reaffirms Their Hold Rating on Bolt Biotherapeutics (BOLT)
TipRanksNov 13 06:19 ET · Ratings

Comments

Jaguar8

Nov 7 09:05

NEWS

$Bolt Biotherapeutics (BOLT.US)$
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting
Bolt Biotherapeutics (BOLT) presented updated preclinical data for BDC-4182, their next-generation Boltbody™ ISAC targeting claudin 18.2, and findings from Phase 1 dose-escalation trial of BDC-1001 at SITC. BDC-4182 showed superior efficacy compared to claudin 18.2 ADCs in preclinical studies, demonstr...

Trytosaveabit

May 15 07:24

Ouch!

$Bolt Biotherapeutics (BOLT.US)$ MT Newswires· 2 mins ago
Bolt Biotherapeutics (BOLT) shares were nearly 32% lower in premarket activity Wednesday following the company's announcement late Tuesday that it will stop the development of trastuzumab imbotolimod, BDC-1001, and has trimmed its workforce by about 50%.
The company said the BDC-1001 program is not expected to meet its pre-defined success criteria and it will now focus on developing its other cancer pipeline, which includes a first-in...

Trytosaveabit

Dec 5, 2023 06:03

Update

$Bolt Biotherapeutics (BOLT.US)$ Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu® 2 MINUTES AGO, 7:00 AM EST VIA GLOBENEWSWIRE

1

Trytosaveabit

Nov 9, 2023 16:28

Call it a win.

$Bolt Biotherapeutics (BOLT.US)$ Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.50) by 14 percent. This is a 25.86 percent increase over losses of $(0.58) per share from the same period last year. The company reported quarterly sales of $2.53 million which beat the analyst consensus estimate of $1.72 million by 46.98 percent. This is a 19.70 percent increase over sales of $2.11 million the same perio...

Trytosaveabit

Oct 16, 2023 06:04

WATCHING!

$Bolt Biotherapeutics (BOLT.US)$ Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023

BOLT Bolt Biotherapeutics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target